Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Voyager-V1 + pembrolizumab + ipilimumab + nivolumab
- Development stage
- Unknown
- Lead developer
- Vyriad
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
Voyager-V1 + pembrolizumab + ipilimumab + nivolumab is an investigational combination immunotherapy regimen developed by Vyriad for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), neuroendocrine carcinoma (NEC), and head and neck cancer. The regimen combines Voyager-V1 (VV1)—an oncolytic vesicular stomatitis virus (VSV) engineered to express human interferon-beta (IFNβ) to enhance anti-tumor immune responses and the human sodium iodide symporter (NIS) for non-invasive SPECT/PET imaging—with immune checkpoint inhibitors. These checkpoint inhibitors include pembrolizumab (an anti-PD-1 monoclonal antibody) or the combination of ipilimumab (an anti-CTLA-4 monoclonal antibody) and nivolumab (an anti-PD-1 monoclonal antibody). By combining direct viral-mediated oncolysis and localized interferon-beta expression with systemic immune checkpoint blockade, the regimen aims to convert immunologically 'cold' tumors into 'hot' tumors, thereby enhancing anti-tumor T-cell responses and overcoming resistance to single-agent checkpoint inhibition.
- Other names
- VSV-IFNβ-NIS + pembrolizumab + ipilimumab + nivolumabVSV-IFNβ-NIS + pembrolizumab or ipilimumab/nivolumabVV1 + pembrolizumab + ipilimumab + nivolumabVoyager-V1 + pembrolizumab + ipilimumab/nivolumabVoyager-V1 + pembrolizumab or ipilimumab + nivolumabVoyager-V1 + pembrolizumab or ipilimumab/nivolumab
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Voyager-V1 + pembrolizumab + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voyager-V1 + pembrolizumab + ipilimumab + nivolumab.